These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25163707)

  • 1. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
    Hughes B; Griffiths P
    Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to commentaries.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The legal regulation of narcotic drugs and psychotropic substances in the Union of Soviet Socialist Republics.
    Babayan EA
    Bull Narc; 1990; 42(1):73-81. PubMed ID: 2095939
    [No Abstract]   [Full Text] [Related]  

  • 8. Controlling new drugs under marketing regulations.
    Hughes B; Winstock AR
    Addiction; 2012 Nov; 107(11):1894-9. PubMed ID: 22288473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Zealand to establish fit for purpose regulation for new psychoactive substances.
    Sheridan J; Atmore B; Russell B
    Addiction; 2012 Nov; 107(11):1901-2. PubMed ID: 23039748
    [No Abstract]   [Full Text] [Related]  

  • 10. New psychoactive substances: issues about the new approach from New Zealand government.
    von Diemen L
    Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704
    [No Abstract]   [Full Text] [Related]  

  • 11. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract]   [Full Text] [Related]  

  • 13. Where is the pleasure?
    Ritter A
    Addiction; 2014 Oct; 109(10):1587-8. PubMed ID: 25163703
    [No Abstract]   [Full Text] [Related]  

  • 14. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
    Wilkins C
    Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective.
    Duffert A
    Drug Test Anal; 2014; 6(7-8):876-8. PubMed ID: 24415657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel psychoactive drugs: has it ended?
    Nichols DE
    J Psychoactive Drugs; 1987; 19(1):33-7. PubMed ID: 3585593
    [No Abstract]   [Full Text] [Related]  

  • 17. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
    Rizwan SB; Vernall AJ
    BMJ; 2017 Mar; 356():j1195. PubMed ID: 28314708
    [No Abstract]   [Full Text] [Related]  

  • 19. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic legislation of new psychoactive drugs.
    van Amsterdam J; Nutt D; van den Brink W
    J Psychopharmacol; 2013 Mar; 27(3):317-24. PubMed ID: 23343598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.